Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Baricitinib is effective and safe for treating alopecia areata.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

5% topical minoxidil improves hair density and quality in monilethrix patients.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Topical Ruxolitinib may safely treat severe hair loss.

Drugs targeting EMT molecules show promise for treating lichen planopilaris.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Adverse events from vismodegib can be managed effectively to ensure optimal treatment.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

Tigason improved hair growth in a boy with monilethrix without side effects.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.